Mechanism of HCV's resistance to IFN-α in cell culture involves expression of functional IFN-α receptor 1

Virology Journal

Volumn 8, Issue , 2011, Pages

  Datta, Sibnarayan ^a   Hazari, Sidhartha ^a   Chandra, Partha ^a   Samara, Maria ^a   Poat, Bret ^a   Gunduz, Feyza ^a   Wimley, William ^a   Hauser, Hansjorg ^b   Koster, Mario ^b   Lamaze, Christophe ^c   Balart, Luis ^a   Garry, Robert ^a   Dash, Srikanta ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c INSTITUT CURIE   (France)

Author keywords

ER stress; HCV infection; Hepatitis C virus (HCV); Interferon alpha (IFN ); Interferon alpha receptor 1 (IFNAR1); Jak Stat signaling; nuclear translocation; reverse transcription polymerase chain reaction (RT PCR)

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; ALPHA2 INTERFERON; JANUS KINASE 1; PROTEIN KINASE TYK2; STAT1 PROTEIN; STAT2 PROTEIN; ALPHA BETA INTERFERON RECEPTOR; IFNAR1 PROTEIN, HUMAN;

ARTICLE; CELL CULTURE; CELL LINE; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FLOW CYTOMETRY; HEPATITIS C VIRUS; MOLECULAR CLONING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; VIRUS REPLICATION; VIRUS RESISTANCE; WESTERN BLOTTING; BIOSYNTHESIS; GENE DELETION; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; LIVER CELL; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS CULTURE;

HEPATITIS C VIRUS;

CELL LINE; GENE EXPRESSION; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; RECEPTOR, INTERFERON ALPHA-BETA; SEQUENCE DELETION; SIGNAL TRANSDUCTION; VIRUS CULTIVATION;

EID: 79960559175     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-351     Document Type: Article

References (33)

1. Acute Hepatitis C: a multifaceted disease. Heller B Rehermann T, Semin Liv Dis 2005 25 7 17 10.1055/s-2005-864778 (Pubitemid 40322347)
2. Global challenges in liver disease. William R, Hepatology 2006 44 521 526 10.1002/hep.21347 16941687
3. Viral Hepatitis C. Poynard T Yuen MF, Ratziu V Lai CL, Lancet 2003 362 2095 2100 10.1016/S0140-6736(03)15109-4 14697814
4. Diagnosis, management, and treatment of hepatitis C: An update. Ghanay MG Strader DB, Thomas DL Seeff LB, Hepatology 2009 49 1335 1374 10.1002/hep.22759 19330875
5. Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Hazari S Taylor L, Haque S Garry RF, Florman S Luftig R, Regenstein F Dash S, Virol J 2007 18 89
6. Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Hazari S Chandra PK Poat B Datta S, Garry RF Foster TP, Kousoulas G Wakita T, Dash S,, Virol J 2010 7 36 10.1186/1743-422X-7-36 20149251
7. Activation of interferon stimulated response element in a Huh-7 cell line replicating hepatitis C virus sub-genomic RNA. Pai M Prabhu R, Panebra A Nangle S, Haque S Bastian F, Garry RF Agrawal K, goodbourn S Dash S, Intervirology 2005 48 301 311 10.1159/000085099 15956798 (Pubitemid 40868964)
8. Palmitoylation of interferon-alpha (IFN-) receptor subunit IFNAR1 is required for the activation of Stat1 and Stat2 by IFN-alpha. Claudinon J Gonnord P Beslard E Marchetti M, Mitchell K Boularan C, Johannes L Eid P, Lamaze C,, J Biol Chem 2009 284 24328 24340 10.1074/jbc.M109.021915 19561067
9. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. Ragimbeau J Dondi E, Alcover A Eid P, Uze G Pellegrini S, EMBO J 2003 3 537 547 (Pubitemid 36193598)
10. Definition of the Interferon alpha receptor-binding domain on the Tyk2 kinase. Yan H Piazza F Krishnan K Pine R, Krolewski JJ,, J Biol Chem 1998 273 4046 4051 10.1074/jbc.273.7.4046 9461596
11. Kinase-deficient forms of Jak-1 and Tyk2 inhibit interferon alpha signaling in a dominant manner. Krishna K Pine R Krolewski JJ,, Eur J Biochem 1997 247 298 305 10.1111/j.1432-1033.1997.00298.x 9249040
12. Dynamic redistribution of Stat1 protein in IFN-signaling visualized by GFP fusion proteins. Koster M Hauser H, Eur J Biochem 1999 260 137 144 10.1046/j.1432-1327.1999.00149.x 10091593 (Pubitemid 29095704)
13. The beta-interferon promoter responds to priming through multiple independent regulatory elements. King P Goodbourn S, J Biol Chem 1994 269 30609 30615 7982980 (Pubitemid 24376547)
14. Identification of residues of the IFNAR1 chain of the type I human interferon receptor is critical for ligand binding and biological activity. Cajean-Feroldi C Nosal F, Nardeux PC Gallet X, Guymarho J Baychelier F, Sempe P Tovey MG, Escary JL Eid P, Biochemistry 2004 43 12498 12512 10.1021/bi049111r 15449939 (Pubitemid 39314711)
15. Novel robust hepatitis C virus mouse efficacy model. Zhu Q Oei Y, Mendel DB Garrett EN, Patawaran MB Hollenbach PW, Aukerman SL Weiner AJ, Antimicrob Agents Chemother 2006 50 3260 3268 10.1128/AAC.00413-06 17005803 (Pubitemid 44527496)
16. Detection of hepatitis C virus RNA sequences by polymerase chain reaction in fixed liver tissue. Akyol G Dash S Shieh YS Malter JS, Gerber MA,, Mod Pathol 1992 5 501 504 1344813
17. Mechanisms of type-I and type-II interferon-mediated signaling. Platanias LC, Nat Rev Immunol 2005 5 375 386 10.1038/nri1604 15864272
18. Type I interferon receptors: Biochemistry and Biological functions. De Weerd NA Samarajiwa SA Hertzog PJ,, J Biol Chem 2007 282 20053 20057 10.1074/jbc.R700006200 17502368 (Pubitemid 47099976)
19. Functional cartography of the ectodomain of the type I interferon receptor subunit IFNAR1. Lamken P Gavutis M, Peters I Van der Heyden J, Uze G Piehler J, J Mol Biol 2005 350 476 488 10.1016/j.jmb.2005.05.008 15946680 (Pubitemid 40828908)
20. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Liu J HuangFu WC, Suresh Kumar KG Qian J, Casey JP Hamanka RB, Grigoriadou C Aldabe R, Diehl JA Fuchs SY, Cell Host and Microbe 2008 11 1 8
21. Contribution of genome-wide HCV genetic differences to outcome of interferon based therapy in Caucasian American and African American Patients. Donlin MJ Cannon NA, Aurora R Li J, Wahed AS Di Bisceglie AM, Tavis JE Virahep-C Study Group, PloS One 2010 5 9032 10.1371/journal.pone.0009032 20140258
22. Induction and evasion of innate antiviral response by hepatitis C virus. Lemon SM, J Biol Chem 2010 285 22741 22747 10.1074/jbc.R109.099556 20457596
23. Mitochondria Stat3 supports Ras-dependent oncogenic transformation. Gough DJ Corlett A, Schlessinger K Wegrzyn J, Larner AC Levy DE, Science 2009 324 1713 1716 10.1126/science.1171721 19556508
24. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. Imai Y Tamura S, Tanaka H Hiramastu N, Kiso S Doi Y, Inada M Nagase T, Kitada T Imanaka K, Fukuda K Takehara T, Kasahara A Hayashi N, J Viral Hepat 2010 17 185 191 10.1111/j.1365-2893.2009.01163.x 19709362
25. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Kurokawa M Hiramatsu N Oze T Mochizuki K, Yakushijin T Kurashige N, Inoue Y Igura T, Imanaka K Yamada A, Oshita M Hagiwara H, Mita E Ito T, Inui Y Hijioka T, Yoshihara H Inoue A, Imai Y Kato M, Kiso S Kanto T, Takehara T Kasahara A, Hayashi N,, Hepatol Res 2009 39 432 438 10.1111/j.1872-034X.2008.00477.x 19207583
26. Old and merging therapies in chronic hepatitis C: an update. Deutsch M Hadziyannis SJ, J Viral Hepat 2008 15 2 11 18088238
27. Interferon alpha-2b alone or combinantion with ribavirin as initial treatment for chronic hepatitis C. McHutchison JG Gordon SC, Schiff ER Shiffman ML, Lee WM Rustgi VK, Goodman ZD Ling MH, Cort S Albrecht JK, New Eng J Med 1998 339 1485 1492 10.1056/NEJM199811193392101 9819446
28. Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type 1-interferon receptors. Naka K Takemoto K Abe K Dansako H, Ikeda M Shimotohno K, Kato N,, J Gen Virol 2005 86 2787 2792 10.1099/vir.0.81124-0 16186233 (Pubitemid 41410469)
29. Intrahepatic mRNA levels of type I interferon receptor and interferon stimulated genes in genotype 1b chronic hepatitis C. Taniguchi H Iwasaki Y, Takahashi A Shimomura H, Moriya A Yu PC, Umeoka F Fujioka S, Koide N Shiratori Y, Intervirology 2007 50 32 39 10.1159/000096310 17164555
30. Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. Katsumi M Katsuaki T Satoru S Takehiko K, Masaaki K,, J Clinical Invest 1998 26 135 140
31. Type 1 interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. Fujiwara D Hino K Yamaguchi Y Kubo Y, Yamashita S Uchida K, Konishi T Nakamura H, Korenaga M Okuda M, Okita K,, J Viral Hepat 2004 11 136 140 10.1046/j.1365-2893.2003.00477.x 14996348 (Pubitemid 38365764)
32. Expression of interferon-alpha/beta receptor protein in liver of patients with hepatitis C virus -related chronic liver disease. Meng XW Chi BR Chen LG Zhang LL, Zhuang Y Huang HY, Sun X,, World J Gastroenterol 2005 11 3962 3965 15991303
33. Variants in Interferon-alpha pathway genes and response to pegylated interferon-alpha 2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C Antiviral Long-term treatment against Cirrhosis trial. Welzel TM Morgan TR, Bonkovsky HL Naishadham D, Pfeiffer RM Wright EC, Hutchinson AA Crenshaw AT, Bashirova A Carrington M, Dotrang M Sterling RK, Lindsay KL Fontana RJ, Lee WM Di Bisceglie AM, Ghany MG Gretch DR, Chanock SJ Chung RT, O'Brien TR HALT-C Trial Group, Hepatology 2009 49 1847 1858 10.1002/hep.22877 19434718